Please ensure Javascript is enabled for purposes of website accessibility

Why Advaxis, Inc. Shares Are Soaring 16% Today

By Todd Campbell - Mar 21, 2016 at 1:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A positive trial in canines with bone cancer could have implications for human cancer patients, too.

SOURCE: ADVAXIS, INC.

What: After reporting intriguing data for its cancer therapy in dogs that could have implications for human cancer patients, shares in Advaxis, (ADXS 10.46%) are rallying 15% at 2:00 p.m. EST Monday.

So what: The clinical stage biotech's ADXS-HER2 is being evaluated as a cancer treatment for osteosarcoma, the most common primary bone tumor found in dogs and the most common bone cancer in children and teens.

In the canine study, 18 dogs with surgically treated osteosarcoma were given the immunotherapy and 15 of those dogs showed an antigen-specific response within six months of receiving ADXS-HER2. Importantly, ADXS-HER2 administration resulted in a median survival time of 956 days, which is far superior to the 423 median days historically associated with this cancer.

Now what: ADXS-HER2 is one of Advaxis listeria-based immunotherapies. These therapies are designed to deliver an engineered variation of listeria directly to tumors so that the immune system can identify the tumor and destroy it.

The news could support a conditional launch by Artana Therapeutics (PETX), which has licensed the drug for use in animal health, later this year.

However, we're still a ways away from this drug being proven effective in humans. Advaxis is evaluating three listeria bioengineered therapies in trials, the most advanced of which in human trials is axalimogene filolisbac, a treatment for cervical cancer, head and neck cancer, and anal cancer. It's also working on ADXS-PSA, a drug that's being studied for use alongside Merck & Co's PD-1 drug, Keytruda, in prostate cancer patients.

SOURCE: ADVAXIS, INC.

Overall, the concept of using immunotherapies to battle back against cancer is immensely intriguing and that makes this company one worth adding to a watch list to keep tabs on. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.51 (0.68%) $0.62
Aratana Therapeutics, Inc. Stock Quote
Aratana Therapeutics, Inc.
PETX
Advaxis, Inc. Stock Quote
Advaxis, Inc.
ADXS
$3.59 (10.46%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.